ClinicalTrials.gg
DrugRead study by study

Tirzepatide clinical trials

Also written LY3298176, Mounjaro and Zepbound.

studies test it
191
open now
109
in phase 3
48
first study started
2016
ClinicalTrials.gov finds 317 studies for Tirzepatide. How that becomes 191 here

Every study that search finds has been read, to see whether and how it gives Tirzepatide. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 317Found by its intervention search · See all 317 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 255 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −6
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. 311Give Tirzepatide to participants
  4. −61Observe patients on it, or give it outside a trial
  5. −21Compare another treatment with it
  6. −38Give it beside what is tested
  7. 191Test it: the count on this site

Get an email when these change. Save the Tirzepatide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
13 May 2022 · MOUNJARO · NDA 215866 (FDA, Drugs@FDA)
European Union
15 Sept 2022 · Mounjaro · EMEA/H/C/005620 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tirzepatide
164
Spartina
3
Dual GIP/GLP-1 receptor agonist
2
Tirzepatide (Flexible titration)
2
Tirzepatide 2.5mg weekly
2

Brand

Mounjaro
23
Zepbound
17

Development codes

LY3298176
69

Studies by the year they started

187 studies that test it; most in 2026 (67); 4 more planned to start later

Studies that test Tirzepatide, by start year
YearStudies
20161
20174
20182
201913
20209
20216
20226
202315
202419
202545
202667

By phase

A phase 1/2 study counts in both.

Early Phase 1
6
Phase 1
27
Phase 2
54
Phase 3
48
Phase 4
42
No phase
19

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 72 · Other 119

Eli Lilly and Company (69) · The Cleveland Clinic (4) · Mayo Clinic (4) · University of Texas Southwestern Medical Center (3) · University Medical Centre Ljubljana (3) · Stanford University (3) · Shahid Beheshti University of Medical Sciences (3) · Zagazig University (2)

Often tested with

Tested in the same studies.

Semaglutide (23) · Bimagrumab (3) · Dulaglutide (2) · Pioglitazone (2) · Bupropion hydrochloride, naltrexone hydrochoride drug combination (1) · Phentermine (1) · Topiramate (1) · Dual GIP/GLP-1 Receptor Agonist (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

Tirzepatide is the comparator. A study of two new drugs counts under both.

  • 1Retatrutide · Eli Lilly and Company · next primary completion Nov 2026
  • 1Enicepatide · Hoffmann-La Roche · next primary completion Apr 2029
  • 1Berobenatide · Pfizer · next primary completion Feb 2028
New treatments tested with it · 8 most studied

New when their studies opened, with Tirzepatide beside them; studies of each.

Reaching primary completion within a year · 47, 6 in phase 3

Studies that test Tirzepatide, phase 3 first.

Studies

Open first, then newest update. How each study uses Tirzepatide has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 191

See all 191 studies that test Tirzepatide →

Behind its US label · 12 — the studies the FDA label of MOUNJARO, ZEPBOUND describes

From the Clinical Studies section of MOUNJARO (2026-08), ZEPBOUND (2026-08), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 147 — no other medicine in its arm

Showing 20 of 147. See all 147 →

Tested with established drugs · 8 — they are given beside it
Tested in a combination · 36 — another drug in the study is under test too

Showing 20 of 36. See all 36 →

Beside an established treatment under test · 1 — an approved drug, surgery or radiation is what the study tests

Tested with Tirzepatide: bremelanotide 1

Beside a new treatment under test · 24 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with Tirzepatide: eloralintide 7 · emugrobart 1 · TLC-6740 1 · mibavademab 1 · apitegromab 1 · bimagrumab 1 · nisotirostide 1 · LAE102 1

Showing 20 of 24. See all 24 →

Beside supportive care · 7 — a supportive treatment or test is studied
Given beside what is tested · 6 — usual care or a partner of the new treatment
As the comparator · 21 — what is tested is compared with Tirzepatide

Showing 20 of 21. See all 21 →

Observed · 61 — patients on it are followed, or it is given outside a trial

Showing 20 of 61. See all 61 →

Codes

What other systems call Tirzepatide · ClinicalTrials.gg INT006887

  • MeSH (NLM) D000098860TirzepatideConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) OYN3CCI6QETIRZEPATIDEConfirmed FDA, NLM, Wikidata
  • RxNorm 2601723One source FDA
  • Wikidata Q108324770tirzepatideConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C174817TirzepatideConfirmed FDA, Wikidata
  • DrugBank DB15171One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion